Necrotizing Fasciitis Market Report 2026

The necrotizing fasciitis market size has grown strongly in recent years. It will grow from $1.17 billion in 2025 to $1.28 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to improvements in surgical debridement techniques, availability of broad-spectrum antibiotics, enhanced intensive care capabilities, growing clinical awareness of severe soft tissue infections, advancements in wound management practices.

The necrotizing fasciitis market size is expected to see strong growth in the next few years. It will grow to $1.82 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to development of targeted antimicrobial therapies, increasing adoption of precision diagnostics, expansion of advanced critical care infrastructure, growing research into immunomodulatory treatments, rising focus on rapid-response infection management protocols. Major trends in the forecast period include increasing focus on early diagnostic interventions, rising adoption of advanced antibiotic regimens, growing use of adjunctive therapies, expansion of multidisciplinary critical care approaches, enhanced emphasis on rapid surgical management.

The increasing incidence of bacterial infections is expected to drive the growth of the necrotizing fasciitis market in the coming years. Bacterial infections occur when harmful bacteria invade and multiply within the body, causing tissue damage and illness. This incidence is rising primarily due to antibiotic resistance, which diminishes the effectiveness of standard treatments and allows infections to persist and spread. A higher incidence of bacterial infections creates a greater risk for severe soft tissue infections, directly supporting the prevalence and rapid progression of necrotizing fasciitis, as opportunistic pathogens exploit weakened host defenses to invade fascial planes quickly. For instance, in March 2024, according to the US Centers for Disease Control and Prevention, tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, a rise of 1,295 cases. Therefore, the rising incidence of bacterial infections is fueling the necrotizing fasciitis market.

The rising healthcare expenditure is expected to further support the growth of the necrotizing fasciitis market. Healthcare expenditure encompasses the total financial resources allocated by governments, private insurers, businesses, and individuals for medical services, treatments, medications, and related health activities. This spending is increasing due to the growing prevalence of chronic diseases, which require ongoing medical management and continuous therapeutic interventions. Greater healthcare expenditure improves the management of necrotizing fasciitis by facilitating access to advanced diagnostics, innovative therapies, and specialized care. For instance, in June 2025, the US Centers for Medicare & Medicaid Services reported that in 2023, national health expenditures increased by 7.5% to $4.9 trillion, averaging $14,570 per person and representing 17.6% of GDP. Medicare spending rose 8.1% to $1.02 trillion, accounting for 21% of total national health expenditures. Therefore, rising healthcare expenditure is driving the market for necrotizing fasciitis.

Companies in the necrotizing fasciitis market are focusing on developing innovative therapies, including antibiotics and immunotherapies, as well as novel wound care solutions. Antibiotics kill or inhibit bacterial growth, while immunotherapies enhance or modify the body’s immune system to combat infections. For example, in March 2025, Altru Health System, a US-based nonprofit physician-led organization, launched Hyperbaric Oxygen Therapy (HBO) to support wound healing in patients with chronic or difficult-to-treat conditions. The therapy delivers 100% oxygen in a pressurized chamber, improving tissue oxygenation and promoting natural healing processes. HBO is used for conditions such as diabetic foot ulcers, radiation-induced tissue damage, compromised skin grafts, and severe infections, providing a non-invasive adjunct to conventional care.

Major companies operating in the necrotizing fasciitis market are GlaxoSmithKline Public Limited Company, Gilead Sciences Inc., Teva Pharmaceutical Industries Limited, Merck And Co. Inc., bioMérieux S.A., Cipla Limited, Dr. Reddy’s Laboratories Limited, Hikma Pharmaceuticals PLC, Mankind Pharma Limited, Wockhardt Limited, Xellia Pharmaceuticals ApS, Basilea Pharmaceutica International Ltd., Avita Medical Inc., HiMedia Laboratories Pvt. Ltd., CutisCare Pvt. Ltd., NovaBay Pharmaceuticals Inc., TCS Biosciences Ltd., 3i Diagnostics Limited, Antabio S.A.P., Pfizer Inc.

North America was the largest region in the necrotizing fasciitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing fasciitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the necrotizing fasciitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the necrotizing fasciitis market by increasing costs of imported pharmaceuticals, surgical instruments, wound care products, and advanced medical devices used in intensive treatment. Hospitals in North America and Europe are most affected due to dependence on imported antibiotics and specialized equipment, while developing regions face higher costs for advanced therapies. These tariffs are increasing treatment expenses and straining hospital procurement budgets. However, they are also encouraging domestic pharmaceutical manufacturing, localized medical supply production, and improved supply chain resilience for critical care products.

The necrotizing fasciitis market research report is one of a series of new reports that provides necrotizing fasciitis market statistics, including necrotizing fasciitis industry global market size, regional shares, competitors with a necrotizing fasciitis market share, detailed necrotizing fasciitis market segments, market trends and opportunities, and any further data you may need to thrive in the necrotizing fasciitis industry. This necrotizing fasciitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Necrotizing fasciitis is a rare but severe and rapidly progressing bacterial infection that leads to extensive destruction of the skin, subcutaneous fat, and fascia, the connective tissue surrounding muscles. Often caused by virulent bacteria such as Streptococcus pyogenes or Staphylococcus aureus, this life-threatening condition is commonly known as flesh-eating disease. Prompt diagnosis and immediate medical intervention are crucial for survival and typically involve broad-spectrum intravenous antibiotics, aggressive surgical debridement, and, in severe cases, intensive supportive care to manage systemic complications such as sepsis and multiorgan failure.

The main treatment types for necrotizing fasciitis include surgical debridement, antibiotic therapy, hyperbaric oxygen therapy, and other approaches. Surgical debridement is a medical procedure that removes dead, infected, or damaged tissue to halt the spread of infection and promote healing. The disease is classified into types I, II, and III, affecting various age groups including pediatric, adult, and geriatric patients. Treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. End-users include hospitals, specialized clinics, emergency care centers, home healthcare providers, and pharmaceutical companies.

The necrotizing fasciitis market includes revenues earned by entities through diagnosis and laboratory testing services, surgical and debridement services, antibiotic and drug therapy management, wound care and infection control services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.